Aclaris therapeutics reports second quarter 2022 financial results and provides a corporate update

Wayne, pa., aug. 03, 2022 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2022 and provided a corporate update.
ACRS Ratings Summary
ACRS Quant Ranking